Rallybio Corp
RLYB
NASDAQ
Biotechnology
$16.99
USD
+0.03 (+0.18%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $90.07M
Volume 12.9K
Revenue
$646,000
TTM
-15.1%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$45.55M
TTM
+209.4%
YoY
Operating Cash Flow
$26.71M
TTM
+163.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.2 | 0.2 | 0.2 | 0.2 | 0.0 |
YoY Growth | -29.1% | -29.1% | +484.2% | 0.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.2 | 0.2 | 0.2 | 0.2 | 0.0 |
Selling, General & Administrative | 4.2 | 3.0 | 3.0 | 6.1 | 4.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 10.3 | 7.1 | 6.6 | 8.9 | 5.7 |
Operating Income | -10.1 | -6.9 | -6.4 | -8.7 | -5.7 |
EBITDA | -10.0 | -6.9 | -6.4 | -8.7 | -5.7 |
Other Income / Expense | -0.2 | 22.5 | 0.0 | 0.3 | 50.4 |
Total Other Income / Expense | 0.4 | 22.9 | 0.6 | 0.5 | 50.6 |
Income Before Income Taxes | -9.7 | 16.0 | -5.9 | -8.3 | 45.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 |
Net Income | -9.7 | 16.0 | -5.9 | -8.3 | 43.7 |
Consolidated Net Income / Loss | -9.7 | 16.0 | -5.0 | -8.3 | 43.7 |
Net Income Attributable to Common Shareholders | -9.7 | 16.0 | -5.9 | -8.3 | 43.7 |
Basic EPS | -$1.73 | $2.88 | -$1.03 | -$1.46 | $7.66 |
Diluted EPS | -$1.73 | $2.88 | -$1.03 | -$1.46 | $7.53 |
Basic Shares Outstanding | 5.6M | 5.6M | 5.7M | 5.7M | 5.7M |
Diluted Shares Outstanding | 5.6M | 5.6M | 5.7M | 5.7M | 5.8M |